Xenogen Products Push Caliper Revenues Up 28 Percent in Q1 as OEM Difficulties Persist | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Caliper Life Sciences said last week that its first quarter revenues rose 28 percent, due primarily to products sold by Xenogen, which Caliper acquired in the second half of last year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.